Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
NVAX 
Novavax Inc (NVAX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: NVAX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $12.5
1 Year Target Price $12.5
| 3 | Strong Buy |
| 1 | Buy |
| 2 | Hold |
| 1 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -79.13% | Avg. Invested days 20 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.36B USD | Price to earnings Ratio 3.78 | 1Y Target Price 12.5 |
Price to earnings Ratio 3.78 | 1Y Target Price 12.5 | ||
Volume (30-day avg) 7 | Beta 2.68 | 52 Weeks Range 5.01 - 15.22 | Updated Date 09/17/2025 |
52 Weeks Range 5.01 - 15.22 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.22 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 39.2% | Operating Margin (TTM) 44.17% |
Management Effectiveness
Return on Assets (TTM) 14.52% | Return on Equity (TTM) -898.2% |
Valuation
Trailing PE 3.78 | Forward PE 2.58 | Enterprise Value 1006515281 | Price to Sales(TTM) 1.26 |
Enterprise Value 1006515281 | Price to Sales(TTM) 1.26 | ||
Enterprise Value to Revenue 0.93 | Enterprise Value to EBITDA 2.03 | Shares Outstanding 162421645 | Shares Floating 136723292 |
Shares Outstanding 162421645 | Shares Floating 136723292 | ||
Percent Insiders 8.76 | Percent Institutions 58.58 |
Upturn AI SWOT
Novavax Inc
Company Overview
History and Background
Novavax, Inc. was founded in 1987. Initially focused on developing new technologies for vaccines, it evolved into a late-stage biotechnology company dedicated to developing and commercializing innovative vaccines to prevent serious infectious diseases.
Core Business Areas
- Vaccine Development and Manufacturing: Novavax focuses on the research, development, and manufacturing of vaccines, particularly recombinant protein vaccines. Their primary focus has been on vaccines for infectious diseases like COVID-19, influenza, and RSV.
Leadership and Structure
Novavax is led by a management team with expertise in vaccine development, manufacturing, and commercialization. The company has a board of directors overseeing its strategic direction.
Top Products and Market Share
Key Offerings
- Nuvaxovid (COVID-19 Vaccine): Novavax's COVID-19 vaccine uses a protein subunit technology. Market share is difficult to pinpoint precisely due to the rapidly evolving vaccine landscape and competition from mRNA vaccines (Pfizer/BioNTech, Moderna) and viral vector vaccines (Johnson & Johnson, AstraZeneca). Initial uptake was slow, but the company is attempting to position the vaccine as a preferred option for those hesitant to receive mRNA vaccines. Competitors include PFE, MRNA, JNJ, AZN.
Market Dynamics
Industry Overview
The vaccine industry is characterized by significant research and development investments, stringent regulatory requirements, and intense competition. The COVID-19 pandemic has accelerated vaccine development and highlighted the importance of rapid vaccine production and distribution.
Positioning
Novavax is positioned as a company offering an alternative vaccine technology (protein subunit) compared to mRNA and viral vector vaccines. Their competitive advantage lies in potentially appealing to a segment of the population hesitant about newer vaccine technologies, as well as being a more established vaccine technology.
Total Addressable Market (TAM)
The global vaccine market is estimated to be hundreds of billions USD, with continued growth expected. Novavax aims to capture a share of this market through its COVID-19 vaccine, and other vaccines in development. TAM is estimated >$50B per year. Novavax's positioning is still uncertain with respect to the TAM.
Upturn SWOT Analysis
Strengths
- Protein subunit vaccine technology
- Established vaccine platform
- Potential for broader acceptance among vaccine-hesitant populations
Weaknesses
- Delayed market entry for COVID-19 vaccine compared to competitors
- Dependence on a limited number of products
- Relatively smaller market capitalization compared to established vaccine giants
- Significant debt
Opportunities
- Expansion into new markets with COVID-19 vaccine
- Development of combination vaccines (e.g., COVID-19/Influenza)
- Partnerships and collaborations to expand product pipeline
- Address unmet needs in developing countries with innovative vaccine solutions
Threats
- Intense competition from established vaccine manufacturers
- Evolving COVID-19 variants requiring vaccine updates
- Changes in regulatory requirements
- Potential for adverse events or safety concerns affecting public perception
- Patent disputes
Competitors and Market Share
Key Competitors
- PFE
- MRNA
- JNJ
- AZN
Competitive Landscape
Novavax faces fierce competition from established vaccine manufacturers with greater resources and market presence. Its protein subunit technology offers a potential advantage in terms of safety perception. However, it lags behind in mRNA development.
Growth Trajectory and Initiatives
Historical Growth: Growth has been inconsistent. Rapid increase during peak vaccine development, but since declined as market demand decreased.
Future Projections: Future growth depends on the successful commercialization of its COVID-19 vaccine, the development of new vaccine candidates, and the ability to secure partnerships and funding.
Recent Initiatives: Focus on combination vaccines (flu/COVID-19), expanding manufacturing capacity, and strengthening relationships with global health organizations.
Summary
Novavax's future hinges on its ability to effectively market its COVID-19 vaccine and develop new products. It is challenged by larger competitors and needs to manage its debt. Successfully navigating the vaccine market, building strategic partnerships, and innovating new solutions will be key to its long-term growth and success. Its protein subunit technology could give it a market advantage with those hesitant about mRNA vaccines.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Market Research Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and subject to change. Consult with a qualified financial advisor before making any investment decisions. All numerical data is based on estimations and may not reflect official figures. All information is up to date as of the time the model was last trained and may not reflect recent activity
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Novavax Inc
Exchange NASDAQ | Headquaters Gaithersburg, MD, United States | ||
IPO Launch date 1995-12-05 | President, CEO & Director Mr. John Charles Jacobs M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 952 | Website https://www.novavax.com |
Full time employees 952 | Website https://www.novavax.com | ||
Novavax, Inc., a biotechnology company, engages in the discovering, developing, and commercializing vaccines to protect against serious infectious diseases in the United States, Europe, and internationally. The company offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response. The company is commercializing a COVID-19 vaccine, NVX-CoV2373 under the brand names of Nuvaxovid, Covovax, and Novavax COVID-19 Vaccine, adjuvanted for adult and adolescent populations as a primary series and for both homologous and heterologous booster indications. It also developing R21/Matrix-M adjuvant malaria vaccine. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.